Long QT syndrome (LQTS) is a hereditary arrhythmia disease. It causes disturbances to the ion flow through cell membranes of cardiomyocytes. These disturbances can sometimes seen in an electrocardiogram (ECG) or 24 hour Holter ECG. LQTS predisposes to cardiac arrhythmia.
Conditions
Interventions
Trade Name: bisoprololi
Pharmaceutical Form: Tablet
INN or Proposed INN: BISOPROLOL
CAS Number: 66722-44-9
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Sponsors
Sydän- ja keuhkokeskus, HUS
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Age 18-65. Genetically confirmed or excluded LQT1-3. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 120 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Ikä ei ole 18-65 vuotta. Geenivirheen olemassaolo yksilöllä epävarma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The objective is to study whether beta-blocker medication stabilizes repolarization in LQT2 patients. Also, the objective is to study repolarization risk factors in high-risk LQTS patients.;Secondary Objective: Not applicable;Primary end point(s): Reduction or appearance of repolarization abnormalities in Holter recordings.;Timepoint(s) of evaluation of this end point: Investigation of Holter recordings, | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Not applicable;Timepoint(s) of evaluation of this end point: Not applicable | — |
Countries
Finland
Contacts
Public ContactKardiologian poliklinikka
Sydän- ja keuhkokeskus, HUS
Outcome results
None listed